Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial

[1]  P. Macfarlane,et al.  Testing cognitive function in elderly populations: the PROSPER study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[2]  John Norrie,et al.  Current Controlled Trials in Cardiovascular Medicine a Prospective Study of Pravastatin in the Elderly at Risk (prosper): Screening Experience and Baseline Characteristics , 2002 .

[3]  K. Yano,et al.  Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study , 2001, The Lancet.

[4]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[5]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[6]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[7]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[8]  J. Kjekshus,et al.  Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). , 1998, The American journal of cardiology.

[9]  A. Weverling-Rijnsburger,et al.  Total cholesterol and risk of mortality in the oldest old , 1997, The Lancet.

[10]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[11]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[12]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[13]  P W Macfarlane,et al.  Automated serial ECG comparison based on the Minnesota code. , 1996, Journal of electrocardiology.

[14]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[15]  A. Hofman,et al.  Cerebral white matter lesions, vascular risk factors, and cognitive function in a population‐based study , 1994, Neurology.

[16]  G. Davey Smith,et al.  Should there be a moratorium on the use of cholesterol lowering drugs? , 1992, BMJ.

[17]  S. Pocock,et al.  Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. , 1991, BMJ.

[18]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.